Tessera Therapeutics
Tessera Therapeutics develops a genome-engineering platform that programs durable genomic alterations using RNA- and DNA-based 'gene writing' approaches. The company combines discovery of mobile genetic element mechanisms, computational candidate screening, engineered gene-writing machineries, and tissue-targeted non-viral lipid nanoparticle delivery to advance preclinical therapeutic programs across liver, hematopoietic stem cells, T cells and lung.
Industries
N/A
Products
Genome engineering platform (RNA and DNA gene writing)
A platform composed of modular RNA- and DNA-based gene-writing systems designed to enable precise and durable genomic alterations for therapeutic purposes.
Genome engineering platform (RNA and DNA gene writing)
A platform composed of modular RNA- and DNA-based gene-writing systems designed to enable precise and durable genomic alterations for therapeutic purposes.
Services
Delivery platform development
Development and optimization of tissue-targeted LNP delivery systems for RNA therapeutics to support in vivo and ex vivo applications.
Delivery platform development
Development and optimization of tissue-targeted LNP delivery systems for RNA therapeutics to support in vivo and ex vivo applications.
Expertise Areas
- Genome engineering using gene-writing approaches
- RNA therapeutics and mRNA platform development
- Non-viral lipid nanoparticle delivery and targeting
- Discovery and engineering of mobile genetic elements
Key Technologies
- Target-primed reverse transcription (TPRT)
- RNA-based gene writers (mRNA + template RNA)
- DNA-based integration without double-stranded breaks
- Lipid nanoparticle (LNP) formulation and targeting